Request ACCRUFeR Samples

Prescribe patients an oral iron they’ll actually take¹. Request a sample today!

ACCRUFeR^® (ferric maltol) is an effective, tolerable, and FDA-approved oral iron treatment for adults with iron deficiency.²

Our Sample Program

Your patients deserve a tolerable oral iron treatment. Put ACCRUFeR to the test with free 5-day samples for your patients. Request ACCRUFeR samples for your office through MySampleCloset.

Request ACCRUFeR samples for your office.

Request Samples

See what sets ACCRUFeR apart.

Our unique "maltol shield" keeps iron intact as it passes through the stomach, reducing the likelihood of reactive oxygen species formation, which in turn minimizes GI side effects.^2,4,6

A 97% median overall treatment compliance was seen during a clinical study’s 12-week randomized period and during a 52-week open-label extension.¹

In a clinical study, ACCRUFeR yielded a 2.25 g/dL mean increase in Hb by Week 12 vs. a 0.06 g/dL increase in the placebo group.

No patients required IV intervention.^1,2,5

Eligible patients may pay as little as $0 with our Patient Savings Program (copay card) or through BlinkRx. Patients will pay no more than $75.

Put ACCRUFeR to the test with free 5-day samples for your patients. Order samples through our portal with MySampleCloset.

Request Samples Now

Connect with one of our representatives or Medical Information, and sign up for updates from Shield Therapeutics.

Resources

Whether you need clinical or access information about ACCRUFeR^® (ferric maltol), or resources for your patients, we’ve got you covered.

References:
1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665.
2. ACCRUFeR^® full prescribing information. Shield Therapeutics, 2023.
4. European Medicines Agency. Accessed March 17, 2021. 
https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf.
5. Gasche C, Ahmad T, Zsolt T, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
6. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846-856.e1. doi:10.1053/j.ajkd.2021.03.0201.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ACCRUFeR is contraindicated in patients with a history of:

Hypersensitivity to ACCRUFeR or any of its inactive components

Hemochromatosis and other iron overload syndromes

Receiving repeated blood transfusions as this may result in iron overload

WARNINGS AND PRECAUTIONS

Increased Risk of Inflammatory Bowel Disease (IBD) Flares

Avoid use of ACCRUFeR in patients with an active IBD flare, as there is potential risk of increased inflammation in the gastrointestinal tract.

Iron Overload

Excessive therapy with iron products can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Do not administer ACCRUFeR to patients with evidence of iron overload or patients receiving intravenous iron. Assess iron parameters prior to initiating ACCRUFeR and monitor iron parameters while on therapy.

Risk of Overdosage in Children Due to Accidental Ingestion

Accidental overdose of iron products is a leading cause of fatal poisoning in children under age 6. Keep out of reach of children.

Request ACCRUFeR Samples

Our Sample Program

Request ACCRUFeR samples for your office.

See what sets ACCRUFeR apart.

Shielded with maltol

Unprecedented tolerability

Established safety and efficacy

Available at the lowest price possible

Put ACCRUFeR to the test with free 5-day samples for your patients. Order samples through our portal with MySampleCloset.